Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer
about
Factors Associated with Adherence to Adjuvant Endocrine Therapy Among Privately Insured and Newly Diagnosed Breast Cancer Patients: A Quantile Regression AnalysisFactors influencing adherence to cancer treatment in older adults with cancer: a systematic reviewRandomized Trial of a Web-Based Intervention to Address Barriers to Clinical TrialsRacial/Ethnic and socioeconomic disparities in endocrine therapy adherence in breast cancer: a systematic reviewAdjuvant therapy use among Appalachian breast cancer survivorsSurviving with lung cancer: medication-taking and oral targeted therapy.Medicare D Subsidies and Racial Disparities in Persistence and Adherence With Hormonal Therapy.Early discontinuation of endocrine therapy for breast cancer: who is at risk in clinical practice?Impact of pharmacy channel on adherence to oral oncolytics.A prospective cohort study of early discontinuation of adjuvant chemotherapy in women with breast cancer: the breast cancer quality of care study (BQUAL).Quality assurance in radiotherapy: analysis of the causes of not starting or early radiotherapy withdrawal.The change from brand-name to generic aromatase inhibitors and hormone therapy adherence for early-stage breast cancer.Joint pain severity predicts premature discontinuation of aromatase inhibitors in breast cancer survivors.Complementary or alternative medicine as possible determinant of decreased persistence to aromatase inhibitor therapy among older women with non-metastatic breast cancer.Household net worth, racial disparities, and hormonal therapy adherence among women with early-stage breast cancer.Population-based assessment of cancer survivors' financial burden and quality of life: a prospective cohort study.Patients' self-reported adherence to capecitabine on XELOX treatment in metastatic colorectal cancer: findings from a retrospective cohort analysis.Race, response to chemotherapy, and outcome within clinical breast cancer subtypes.Racial and Ethnic Differences in Breast Cancer Survival: Mediating Effect of Tumor Characteristics and Sociodemographic and Treatment FactorsFinancial toxicity, Part I: a new name for a growing problem.The introduction of generic aromatase inhibitors and treatment adherence among Medicare D enrollees.Prescription drug coverage: implications for hormonal therapy adherence in women diagnosed with breast cancerPatient-reported discontinuation of endocrine therapy and related adverse effects among women with early-stage breast cancerA Systematic Review of Adherence to Oral Antineoplastic TherapiesAdherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review.Medication taking behaviors among breast cancer patients on adjuvant endocrine therapy.Financial Burden of Cancer Clinical Trial Participation and the Impact of a Cancer Care Equity ProgramThe financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience.Financial Hardship Associated With Cancer in the United States: Findings From a Population-Based Sample of Adult Cancer Survivors2013 updated American Society of Clinical Oncology/Oncology Nursing Society chemotherapy administration safety standards including standards for the safe administration and management of oral chemotherapyEthnic differences in initiation and timing of adjuvant endocrine therapy among older women with hormone receptor-positive breast cancer enrolled in Medicare Part D.Endocrine therapy initiation among Medicaid-insured breast cancer survivors with hormone receptor-positive tumors.Cross-national comparison of medical costs shared by payers and patients: a study of postmenopausal women with early-stage breast cancer based on assumption case scenarios and reimbursement fees.Effect of age on drug metabolism in women with breast cancer.Cancer patients' trade-offs among efficacy, toxicity, and out-of-pocket cost in the curative and noncurative setting.Financial Distress in Cancer Patients.Measuring financial toxicity as a clinically relevant patient-reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST).Barriers and facilitators of adjuvant hormone therapy adherence and persistence in women with breast cancer: a systematic review.Self-reported financial burden and satisfaction with care among patients with cancer.Adherence to long-term adjuvant hormonal therapy for breast cancer.
P2860
Q26779595-0D4718BA-2F64-461C-AB9B-3AEAD0A8FF25Q26850736-742B0CD0-5CAA-4CF7-9773-916E14B17DEFQ27313405-1088E9CD-18C4-422F-A7A0-D04CDA790CD6Q28082674-8C6805AB-2454-4315-A1D7-CC9B14AA11EAQ30279083-7632A23D-7924-4D4A-A350-F0FCC3C49F2EQ30407705-01112060-A81E-4369-8795-47FD766DC272Q33756382-BB8CF666-7C8B-4E39-AB30-66D009FF8D2DQ33756969-B70783DF-7B96-4479-AA02-961E0D76B842Q33815415-FF7D9629-5D58-4076-9DB9-1E6CC9E0DE30Q33857602-AB8D0DD0-75C5-4B74-A637-F945E0F1ADA5Q34676969-EAFBAB37-0A03-4235-AFE5-05C8B3A82BFFQ34736154-0E613AA1-0A73-421C-A35F-42431556C0F6Q34978227-EA6DFB13-0E15-4DF1-93F5-DD427691FC72Q35075218-26F7C33E-8C4F-4E3B-8C83-34EA074AEFA1Q35168777-F3CC6741-8C8F-44A2-B498-1C0D3D41B37AQ35210611-8094253D-E8C8-43C2-A3F1-404CC88398E6Q35444531-8016B073-B4B4-413B-AE0A-341691662F0AQ35568229-0A87ECAA-0811-4E0F-BF83-701E6CE4C094Q35801283-558227E4-3582-4D90-9673-DE6F8C0726D3Q35913404-7F43F20F-1CDC-405C-BCD9-CED071CF2E1DQ36087210-3E04B977-DE4F-4993-8A05-DF28F6BDEFB3Q36300005-AFCB5B9D-559D-46F4-B219-B02CB3A8A04FQ36406107-46E2D983-C82B-4EA6-9934-3FB8ABC784ACQ36673490-472AAF4E-0816-45DA-8967-54308D5D2127Q36713559-687F755B-BCAF-4BB9-A21E-96B37C9365F9Q36775383-E2A7C3F1-AA75-4129-8831-64E15A8E2D05Q36788307-68F30F70-DFD0-4536-B68D-F211EA7CBB86Q36804490-EE8412D3-43E0-4CBF-A7C0-9210BC87ACDEQ36914430-6D668437-4907-4242-AF8C-51745CAD6540Q37063671-EA2417BA-8CF5-4BB4-9195-98D9BD6A6C66Q37070101-C7373ACD-71AC-427A-AA21-DBC92FD58077Q37146389-8120A355-E76E-4B30-B10A-CA9BFCAF2C74Q37255093-7F04D122-3C3A-439B-A2A3-C156270FAC9FQ37325560-23E2190E-962A-4808-9D12-3AF4C4388FCAQ37379577-C5D82793-B0D1-4D82-88DF-C7FEF45B1614Q37384175-C90481BC-E42A-4C0C-9823-C9D08EDF29C9Q37631947-8EF1445D-4FD7-4E02-A63A-D0CDFEB6FE32Q37669380-542419C3-4E56-46F9-A1DE-F735301DFD17Q37698221-4536086E-8137-4746-8A1E-0DA5DD238908Q37958054-7BC76CF5-5FD1-4CDA-9903-0AA0E49C8C3E
P2860
Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Association between prescripti ...... with early-stage breast cancer
@ast
Association between prescripti ...... with early-stage breast cancer
@en
Association between prescripti ...... with early-stage breast cancer
@nl
type
label
Association between prescripti ...... with early-stage breast cancer
@ast
Association between prescripti ...... with early-stage breast cancer
@en
Association between prescripti ...... with early-stage breast cancer
@nl
prefLabel
Association between prescripti ...... with early-stage breast cancer
@ast
Association between prescripti ...... with early-stage breast cancer
@en
Association between prescripti ...... with early-stage breast cancer
@nl
P2093
P2860
P356
P1476
Association between prescripti ...... with early-stage breast cancer
@en
P2093
Alfred I Neugut
Corey H Brouse
Elizabeth Ty Wilde
Milayna Subar
Scott Stratton
Victor R Grann
P2860
P304
P356
10.1200/JCO.2010.33.3179
P407
P577
2011-06-20T00:00:00Z